Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Cartesian Therapeutics (RNAC) over the last 6 years, with Sep 2025 value amounting to -$1.38.
- Cartesian Therapeutics' EPS (Weighted Average and Diluted) fell 22.12% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 97.26%. This contributed to the annual value of -$4.49 for FY2024, which is 90.98% up from last year.
- As of Q3 2025, Cartesian Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.38, which was down 376.00% from $0.50 recorded in Q2 2025.
- Cartesian Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.54 for Q2 2024, and its period low was -$41.56 during Q4 2023.
- Over the past 3 years, Cartesian Therapeutics' median EPS (Weighted Average and Diluted) value was -$1.38 (recorded in 2025), while the average stood at -$5.66.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 3,043.60% in 2022, then plummeted by 83,020.00% in 2023.
- Over the past 5 years, Cartesian Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.12 in 2021, then plummeted by 141.67% to -$0.05 in 2022, then plummeted by 83,020.00% to -$41.56 in 2023, then skyrocketed by 100.29% to $0.12 in 2024, then fell by 22.12% to -$1.38 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.38 for Q3 2025, versus $0.50 for Q2 2025 and -$0.68 for Q1 2025.